ANALYSIS OF EXPRESSION OF CHOLECYSTOKININ IN DOPAMINE CELLS IN THE VENTRAL MESENCEPHALON OF SEVERAL SPECIES AND IN HUMANS WITH SCHIZOPHRENIA

被引：78

作者：

SCHALLING, M

FRIBERG, K

SEROOGY, K

RIEDERER, P

BIRD, E

SCHIFFMANN, SN

MAILLEUX, P

VANDERHAEGHEN, JJ

KUGA, S

GOLDSTEIN, M

KITAHAMA, K

LUPPI, PH

JOUVET, M

HOKFELT, T

机构：

[1] UNIV WURZBURG,DEPT PSYCHIAT,W-8700 WURZBURG,GERMANY

[2] HARVARD UNIV,MCLEAN HOSP,CTR BRAIN TISSUE RESOURCE,SCH MED,BELMONT,MA 02178

[3] UNIV LYON 1,DEPT EXPTL MED,F-69365 LYONS 2,FRANCE

[4] NYU MED CTR,DEPT PSYCHIAT,NEW YORK,NY 10016

来源：

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA | 1990年 / 87卷 / 21期

关键词：

Coexistence; Mental illness; Neuroleptics; Neuropeptide; Substantia nigra;

D O I：

10.1073/pnas.87.21.8427

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The ventral mesencephalons of hamster, guinea pig, cat, monkey, and several humans with and without the diagnosis of schizophrenia were analyzed with in situ hybridization and immunohistochemistry. Extensive codistribution of cholecystokinin mRNA and tyrosine hydroxylase [L-tyrosine, tetrahydropteridine: oxygen oxidoreductase (3-hydroxylating), EC 1.14.16.2] mRNA was observed in cats and monkeys as well as in all five human subjects with the diagnosis of schizophrenia and in two out of five control brains. Double labeling revealed coexistence of the two markers in cat, monkey, and human. No cholecystokinin mRNA or cholecystokinin peptide was detected in the substantia nigra/ventral tegmental area of the hamster or guinea pig, even after acute and chronic neuroleptic treatment.

引用

页码：8427 / 8431

页数：5

共 42 条

[1] ANATASI A, 1967, EXPERIENTIA, V23, P699
[2] THE DISTRIBUTION OF THALAMIC PROJECTION NEURONS CONTAINING CHOLECYSTOKININ MESSENGER-RNA, USING INSITU HYBRIDIZATION HISTOCHEMISTRY AND RETROGRADE LABELING
BURGUNDER, JM
YOUNG, WS
[J]. MOLECULAR BRAIN RESEARCH, 1988, 4 (03): : 179 - 189
[3] CARLSSON A, 1963, ACTA PHARMACOL TOX, V20, P140
[4] CHOLECYSTOKININ-OCTAPEPTIDE EFFECTS ON CONDITIONED-AVOIDANCE BEHAVIOR, STEREOTYPY AND CATALEPSY
COHEN, SL
KNIGHT, M
TAMMINGA, CA
CHASE, TN
[J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1982, 83 (3-4) : 213 - 222
[5] COONS AH, 1958, GENERAL CYTOCHEMICAL, P399
[6] DAHLSTROM A, 1964, ACTA PHYSIOL SCAND, V62, P1
[7] CLONING AND SEQUENCE-ANALYSIS OF A CDNA-ENCODING RAT PREPROCHOLECYSTOKININ
DESCHENES, RJ
LORENZ, LJ
HAUN, RS
ROOS, BA
COLLIER, KJ
DIXON, JE
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (03): : 726 - 730
[8] NEUROLEPTIC-LIKE PROPERTIES OF CHOLECYSTOKININ ANALOGS - DISTINCTIVE MECHANISMS UNDERLYING SIMILAR BEHAVIORAL PROFILES DEPENDING ON THE ROUTE OF ADMINISTRATION
DEWITTE, P
GEWISS, M
ROQUES, B
VANDERHAEGHEN, JJ
[J]. PEPTIDES, 1988, 9 (04) : 739 - 743
[9] DOCKRAY G J, 1981, Neurochemistry International, V3, P281, DOI 10.1016/0197-0186(81)90014-0
[10] VERTEILUNG VON NORADRENALIN UND DOPAMIN (3-HYDROXYTYRAMIN) IM GEHIRN DES MENSCHEN UND IHR VERHALTEN BEI ERKRANKUNGEN DES EXTRAPYRAMIDALEN SYSTEMS
EHRINGER, H
HORNYKIEWICZ, O
[J]. KLINISCHE WOCHENSCHRIFT, 1960, 38 (24): : 1236 - 1239

← 1 2 3 4 5 →